These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31254552)

  • 41. Harnessing cancer immunotherapy during the unexploited immediate perioperative period.
    Matzner P; Sandbank E; Neeman E; Zmora O; Gottumukkala V; Ben-Eliyahu S
    Nat Rev Clin Oncol; 2020 May; 17(5):313-326. PubMed ID: 32066936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conference scene: Immune signatures in the tumor and beyond.
    Kandalaft LE; Kalos M; Melief CJ; Speiser DE; Coukos G
    Immunotherapy; 2012 Aug; 4(8):761-72. PubMed ID: 22947003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics.
    Hong E; Dobrovolskaia MA
    Adv Drug Deliv Rev; 2019 Feb; 141():3-22. PubMed ID: 29339144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
    Patel SA; Minn AJ
    Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer vaccines: translation from mice to human clinical trials.
    Maeng H; Terabe M; Berzofsky JA
    Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
    Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
    J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The promising alliance of anti-cancer electrochemotherapy with immunotherapy.
    Calvet CY; Mir LM
    Cancer Metastasis Rev; 2016 Jun; 35(2):165-77. PubMed ID: 26993326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in immunotherapy delivery from implantable and injectable biomaterials.
    Leach DG; Young S; Hartgerink JD
    Acta Biomater; 2019 Apr; 88():15-31. PubMed ID: 30771535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanoparticles for tumor immunotherapy.
    Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
    Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracorporeal shock waves: perspectives in malignant tumor treatment.
    Frairia R; Berta L; Catalano MG
    J Biol Regul Homeost Agents; 2016; 30(3):641-648. PubMed ID: 27655480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses.
    Chen Q; Chen M; Liu Z
    Chem Soc Rev; 2019 Nov; 48(22):5506-5526. PubMed ID: 31589233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?
    Zöller M
    Technol Cancer Res Treat; 2003 Jun; 2(3):237-60. PubMed ID: 12779354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy and radiation.
    Hiniker SM; Knox SJ
    Semin Oncol; 2014 Dec; 41(6):702-13. PubMed ID: 25499631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer.
    Tian Y; Liu Z; Tan H; Hou J; Wen X; Yang F; Cheng W
    Int J Nanomedicine; 2020; 15():401-418. PubMed ID: 32021187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.
    Curtin JF; King GD; Candolfi M; Greeno RB; Kroeger KM; Lowenstein PR; Castro MG
    Curr Top Med Chem; 2005; 5(12):1151-70. PubMed ID: 16248789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tracking cellular and immune therapies in cancer.
    Kurtz DM; Gambhir SS
    Adv Cancer Res; 2014; 124():257-96. PubMed ID: 25287692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.